Regeneron Pharmaceuticals IncNASDAQ:REGN
- LAST PRICE982.2900
- TODAY'S CHANGE (%)14.3100 (1.4783%)
- Bid / Lots967.0000/ 3
- Ask / Lots990.0000/ 2
- Open / Previous Close969.2700 / 967.9800
- Day Range
- 52 Week Range
- Volume386,559
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | REGN |
|---|---|---|
| 09:32 ET | 23270 | 969.27 |
| 09:34 ET | 1100 | 967.77 |
| 09:36 ET | 500 | 967.77 |
| 09:38 ET | 312 | 966 |
| 09:39 ET | 1037 | 966.39 |
| 09:41 ET | 700 | 966.99 |
| 09:45 ET | 400 | 967.72 |
| 09:48 ET | 800 | 968.795 |
| 09:50 ET | 100 | 968.8 |
| 09:52 ET | 400 | 969.09 |
| 09:57 ET | 734 | 969.03 |
| 09:59 ET | 1300 | 969.4 |
| 10:01 ET | 4671 | 970.52 |
| 10:03 ET | 376 | 970.99 |
| 10:06 ET | 100 | 970.95 |
| 10:08 ET | 4458 | 970.69 |
| 10:10 ET | 100 | 970.7998 |
| 10:12 ET | 2042 | 971.79 |
| 10:17 ET | 127 | 972.14 |
| 10:19 ET | 100 | 971.46 |
| 10:24 ET | 960 | 973.7 |
| 10:26 ET | 200 | 972.65 |
| 10:28 ET | 205 | 974.27 |
| 10:30 ET | 400 | 973.43 |
| 10:32 ET | 375 | 973.505 |
| 10:33 ET | 500 | 972.615 |
| 10:37 ET | 400 | 972.04 |
| 10:39 ET | 3654 | 973.325 |
| 10:42 ET | 502 | 972.615 |
| 10:44 ET | 200 | 972.05 |
| 10:46 ET | 412 | 973.125 |
| 10:48 ET | 300 | 973 |
| 10:50 ET | 604 | 972.13 |
| 10:51 ET | 2374 | 973.7375 |
| 10:53 ET | 100 | 972.89 |
| 10:55 ET | 300 | 973.17 |
| 10:57 ET | 100 | 973.02 |
| 11:00 ET | 2698 | 973.09 |
| 11:02 ET | 602 | 973.575 |
| 11:04 ET | 100 | 973.64 |
| 11:06 ET | 1401 | 973.82 |
| 11:08 ET | 663 | 973.32 |
| 11:09 ET | 504 | 973.655 |
| 11:11 ET | 300 | 973.48 |
| 11:13 ET | 2150 | 976.34 |
| 11:15 ET | 600 | 976.58 |
| 11:18 ET | 100 | 976.46 |
| 11:20 ET | 300 | 976.39 |
| 11:26 ET | 548 | 976.3775 |
| 11:29 ET | 202 | 976.03 |
| 11:31 ET | 508 | 976.515 |
| 11:36 ET | 227 | 976 |
| 11:38 ET | 200 | 976.01 |
| 11:44 ET | 1009 | 977.2 |
| 11:45 ET | 341 | 977.95 |
| 11:47 ET | 207 | 977.285 |
| 11:49 ET | 100 | 977.4 |
| 11:51 ET | 500 | 977.76 |
| 11:54 ET | 741 | 977.25 |
| 11:56 ET | 116 | 977.15 |
| 11:58 ET | 3225 | 978.31 |
| 12:00 ET | 200 | 977.97 |
| 12:02 ET | 400 | 977.7 |
| 12:03 ET | 892 | 978.68 |
| 12:09 ET | 200 | 978.76 |
| 12:12 ET | 1364 | 979 |
| 12:14 ET | 100 | 979.055 |
| 12:18 ET | 300 | 978.905 |
| 12:20 ET | 4696 | 979.475 |
| 12:21 ET | 11424 | 980.16 |
| 12:23 ET | 100 | 979.425 |
| 12:25 ET | 100 | 979.24 |
| 12:27 ET | 1009 | 978.69 |
| 12:32 ET | 200 | 977.99 |
| 12:34 ET | 200 | 978.52 |
| 12:36 ET | 400 | 979.1 |
| 12:38 ET | 100 | 978.3 |
| 12:41 ET | 200 | 979.03 |
| 12:43 ET | 300 | 978.495 |
| 12:48 ET | 700 | 978.43 |
| 12:50 ET | 100 | 978.395 |
| 12:52 ET | 300 | 978.515 |
| 12:56 ET | 100 | 978.59 |
| 12:59 ET | 500 | 978.14 |
| 01:01 ET | 500 | 978.5 |
| 01:03 ET | 197 | 978.08 |
| 01:06 ET | 200 | 978.105 |
| 01:08 ET | 200 | 977.88 |
| 01:10 ET | 2100 | 979 |
| 01:17 ET | 210 | 979.045 |
| 01:21 ET | 425 | 979.1 |
| 01:28 ET | 645 | 979.55 |
| 01:30 ET | 1500 | 979.08 |
| 01:32 ET | 1647 | 978.64 |
| 01:35 ET | 400 | 979 |
| 01:37 ET | 464 | 978.485 |
| 01:42 ET | 601 | 978.61 |
| 01:44 ET | 100 | 978.23 |
| 01:46 ET | 804 | 978.365 |
| 01:48 ET | 1295 | 978.37 |
| 01:50 ET | 1900 | 978.921 |
| 01:53 ET | 247 | 978.915 |
| 01:57 ET | 100 | 978.95 |
| 02:00 ET | 194 | 979.46 |
| 02:02 ET | 509 | 978.945 |
| 02:04 ET | 1000 | 979.66 |
| 02:06 ET | 204 | 979.1 |
| 02:09 ET | 100 | 979.73 |
| 02:13 ET | 100 | 979.335 |
| 02:20 ET | 500 | 979 |
| 02:22 ET | 700 | 979.53 |
| 02:24 ET | 600 | 978.97 |
| 02:27 ET | 100 | 979.37 |
| 02:29 ET | 6582 | 979.235 |
| 02:31 ET | 100 | 979.19 |
| 02:38 ET | 100 | 978.99 |
| 02:40 ET | 800 | 978.825 |
| 02:42 ET | 1448 | 978.155 |
| 02:44 ET | 106 | 978.305 |
| 02:45 ET | 300 | 977.97 |
| 02:47 ET | 200 | 978.015 |
| 02:49 ET | 419 | 978.725 |
| 02:51 ET | 301 | 978.63 |
| 02:54 ET | 1061 | 978.19 |
| 02:56 ET | 507 | 978.26 |
| 02:58 ET | 415 | 978.3 |
| 03:00 ET | 296 | 978.2 |
| 03:02 ET | 100 | 978.165 |
| 03:03 ET | 2622 | 978.465 |
| 03:05 ET | 1100 | 978.485 |
| 03:07 ET | 3515 | 978.815 |
| 03:09 ET | 2694 | 978.59 |
| 03:12 ET | 920 | 980.5105 |
| 03:14 ET | 991 | 979.7 |
| 03:18 ET | 200 | 979.9077 |
| 03:20 ET | 200 | 979.9 |
| 03:21 ET | 499 | 980.11 |
| 03:23 ET | 300 | 979.885 |
| 03:27 ET | 100 | 979.795 |
| 03:30 ET | 200 | 980.15 |
| 03:32 ET | 1721 | 980.075 |
| 03:34 ET | 986 | 979.85 |
| 03:36 ET | 100 | 979.63 |
| 03:39 ET | 300 | 979.475 |
| 03:41 ET | 300 | 979.69 |
| 03:43 ET | 759 | 979.53 |
| 03:45 ET | 200 | 979.24 |
| 03:48 ET | 100 | 979.31 |
| 03:50 ET | 1143 | 979.55 |
| 03:52 ET | 1271 | 980.0825 |
| 03:54 ET | 500 | 979.86 |
| 03:56 ET | 5110 | 980.46 |
| 03:57 ET | 864 | 981.98 |
| 03:59 ET | 2533 | 982.29 |
Today
Yesterday
May 17, 2024
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024, from 1:45PM ET on Friday May 17, 2024 by Dow Jones
1:45PM ET on Friday May 17, 2024 by Dow JonesIMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 1:00PM ET on Friday May 17, 2024 by Dow Jones
1:00PM ET on Friday May 17, 2024 by Dow Jones
May 16, 2024
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN), from 3:54PM ET on Thursday May 16, 2024 by Dow Jones
3:54PM ET on Thursday May 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regeneron Pharmaceuticals Inc | 108.2B | 29.0x | +10.93% |
Vertex Pharmaceuticals Inc | 114.9B | 28.9x | +46.35% |
IQVIA Holdings Inc | 42.1B | 31.5x | +46.62% |
Biogen Inc | 33.6B | 28.8x | -18.14% |
Moderna Inc | 50.9B | -8.5x | --- |
ICON PLC | 26.0B | 38.2x | +4.68% |
Company Information
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
Contact Information
- Headquarters
- 777 Old Saw Mill River RoadTARRYTOWN, NY, United States 10591
- Phone
- 781-370-5000
- Fax
- ---
Executives
- Co-Chairman of the Board, President, Chief Executive Officer, Founder
- Leonard Schleifer
- Co-Chairman of the Board, President, Chief Scientific Officer
- George Yancopoulos
- Chief Financial Officer, Senior Vice President - Finance
- Christopher Fenimore
- Executive Vice President, General Counsel, Secretary
- Joseph LaRosa
- Executive Vice President, General Manager - Industrial Operations and Product Supply
- Daniel Van Plew
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $108.2B |
|---|---|
Revenue (TTM) | $13.1B |
Shares Outstanding | 110.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.13 |
EPS | $33.86 |
Book Value | $237.41 |
P/E Ratio | 29.0x |
Price/Sales (TTM) | 8.3 |
Price/Cash Flow (TTM) | 25.2x |
Operating Margin | 29.40% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
